Lefortovsky Branch of FSUE Endopharm along with the Ministry of Industry and Trade of Russia implement a large-scale investment project for the reconstruction and technical re-equipment of production. Center for Development of Biotechnological and Innovative Medicinal Products has been put into operation being the first stage of the project implementation.
Mr. Mikhail Fonarev, General Director of FSUE Endopharm said that “over 75% of medicinal products manufactured by FSUE Endopharm have been included in the list of vital and essential drugs. We provide socially significant products to all subjects of the Russian Federation. In the current geopolitical and economic situation, the Company invests in the development and production of science-intensive high-tech products ensuring the availability of modern popular medicines for the citizens of the country”.
“425 million rubles have been invested in the creation of the Center for Development of Biotechnological and Innovative Medicinal Products of FSUE Endopharm of which 300 million rubles have been spent on the purchase of laboratory equipment. Until 2025, a large industrial complex with modern research and laboratory facilities is being organized in the Lefortovsky Branch of FSUE Endopharm. The total investment volume accounts for 9.9 billion rubles of which 6.6 billion rubles are at the expense of the Company's own funds,” commented Mr. Dmitry Averyanov, Deputy General Director, Director of Lefortovsky Branch of FSUE Endopharm.
Director of Lefortovsky Branch emphasized that the support measures provided to the Plant by the Government of the Russian Federation and the Government of Moscow help to maintain the planned pace of work on the implementation of investment projects.
“The 700-square-meter facility houses six laboratories equipped with modern equipment including domestic production with more than 30 high technology jobs that have appeared there,” said Mr. Vladimir Yefimov, Deputy Moscow Mayor for Economic Policy and Property and Land Relations.
At present, the number of scientific personnel of the Center is more than 30 employees. The average salary of a research worker is 180 thousand rubles.
At the current stage, the tasks of the Center for Development of Biotechnological and Innovative Medicines include the development and improvement of production technologies for more than 60 active pharmaceutical ingredients, as well as high-tech drugs obtained by:
o genetic engineering methods used to treat the reproductive system;
o peptide synthesis method for the treatment of diseases of the endocrine system and metabolic syndrome;
o methods of chemical synthesis of a new generation of selective inhibitors of blood coagulation factors, hypoglycemic agents, neuroleptics, anxiolytics, muscle relaxants and non-inhalation drugs for anesthesia.
“In 2021, the city signed an offset contract with the Moscow Endocrine Plant. The volume of investments for it is one billion rubles. According to the contract, the investor must localize the manufacture of 20 drugs in the city within two years. Moscow, in turn, guarantees the purchase of medicinal products for 1.1 billion rubles over eight years,” said Mr. Vladislav Ovchinsky, Head of Moscow Department of Investment and Industrial Policy.
The reconstruction and technical re-equipment of the scientific and laboratory building is being carried out at the same site for the creation of a modern R&D complex with a total area of 6,200 m² equipped with appropriate analytical and pilot equipment.
The complex includes:
– a site for the development of processes for the production of active pharmaceutical ingridients obtained by chemical synthesis from plant and animal raw materials;
– analytical laboratories and laboratories for the development and transfer of advanced technologies for the production of finished drugs;
– a pilot production site for the production of medicines including for the performance of clinical trials;
– microbiological and chemical laboratories for quality control of raw materials and products;
– a full-scale site for the development and production of reference materials.
“The laboratory complex which we opened at the site of the Moscow Endocrine Plant will be responsible not only for the development of production of already known classes of drugs but also for the creation of new competencies in this area at the enterprise, including the development of biological drugs. This laboratory complex is also a good cluster cell, on the basis of which many manufacturers will have the opportunity to combine their efforts both in terms of using highly qualified staff and in terms of filling with laboratory and analytical equipment, control samples necessary for pharmaceutical production and performing various technological operations. These are standard samples of the Moscow Endocrine Plant itself, the number of which will be increased, including within the framework of already existing state programs. I am sure that in a short time the cluster will strengthen and grow larger, which will open up new opportunities for pharmaceutical manufacturers,” said Mr. Dmitry Galkin, Director of Department for Development of Pharmaceutical and Medical Industry of the Russian Ministry of Industry and Trade.
The second stage of the investment project implementation will be the commissioning of a high technology production facility at the Lefortovsky Branch capable of annually producing 73 million drugs in ampoules and vials including lyophilized drugs and emulsions, circa 1 billion tablets and capsules, 10 million drugs in the form of sprays as well as 33 million transdermal patches and transmucosal films based on the Company's own developments.
Among other things, the investment projects of FSUE Endopharm are implemented through the provision of subsidies for capital investments by the Ministry of Industry and Trade of Russia. The preferential lending rates for industrial enterprises help to use the current assets more efficiently.
The Moscow government also actively supports the enterprise. Since 2016, FSUE Endopharm has the status of Industrial Complex which allows for receiving tax benefits and subsidies for lease payments from the city, freeing up additional funds to expand production activities and research and development.
Moscow helps the enterprise with the development of infrastructure. The free passage is organized to the Lefortovsky Branch. The illegal buildings have been demolished, the roadbed has been laid, the sidewalks and lighting have been organized and the territory has been landscaped. The issues related to changes in the land use and development rules are being resolved; the red lines of the street and road network are being adjusted for the arrangement of a second car access to the Lefortovsky Branch from the center.
In the near future, by the proposal of the Company, a decision on the assignment of the appellation of “Moscow Chemists’ Street” or “Chemists’ Street” to Projected Passage No. 2095 of the City of Moscow is expected where the capital buildings of the Lefortovsky Branch are located.
Comment type is not specified in the component properties.